Daraxonrasib doubles pancreatic-cancer survival; aficamten, Vyvgart land key approvals

Revolution Medicines' pan-RAS inhibitor daraxonrasib achieved 13.2 months median overall survival in metastatic pancreatic cancer versus 6.7 months for chemotherapy alone—nearly double—in phase 3, with FDA fast-track and expanded-access approval granted. Cytokinetics announced May 5 that aficamten (Myqorzo) met its primary endpoint in the ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy. Argenx won FDA approval May 8 for Vyvgart's expansion to all serum types of myasthenia gravis. BioCentury logged seven biotech M&A deals in early May, three exceeding $1B.